Skip to main content

Table 2 Baseline demographic and clinical characteristics of the enrolled population

From: Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Characteristic Placebo (n=88) Apremilast BID Total (N=352)
   10 mg (n=89) 20 mg (n=87) 30 mg (n=88)  
Age (years) 44.1 ± 13.7 44.4 ± 14.0 44.6 ± 12.6 44.1 ± 14.7 44.3 ± 13.7
Male 53 (60.2) 63 (70.8) 55 (63.2) 50 (56.8) 221 (62.8)
Race      
   White 83 (94.3) 82 (92.1) 82 (94.3) 80 (90.9) 327 (92.9)
   Black 1 (1.1) 2 (2.2) 1 (1.1) 2 (2.3) 6 (1.7)
   Asian 4 (4.5) 3 (3.4) 2 (2.3) 4 (4.5) 13 (3.7)
   Other 0 (0.0) 2 (2.2) 2 (2.3) 2 (2.3) 6 (1.7)
Height (cm) 171.2 ± 8.6 171.5 ± 10.2 171.7 ± 9.6 171.2 ± 10.7 171.5 ± 9.6
Weight (kg) 90.3 ± 21.4 95.7 ± 23.2 89.9 ± 20.2 91.2 ± 23.1 91.8 ± 22.0
BMI (kg/m2) 30.8 ± 6.7 32.5 ± 7.4 30.4 ± 6.2 31.1 ± 7.8 31.2 ± 7.1
Total PASI score 18.1 ± 5.7 18.1 ± 6.3 18.5 ± 7.3 19.1 ± 7.1 18.5 ± 6.6
BSA 21.0 ± 11.2 21.3 ± 11.4 20.7 ± 12.4 25.0 ± 15.4 22.0 ± 12.8
+ History PsA 17 (19.3) 20 (22.5) 16 (18.4) 21 (23.9) 74 (21.0)
Plaque psoriasis history (years) 19.6 ± 11.6 18.0 ± 12.4 19.2 ± 12.2 19.2 ± 12.0 19.0 ± 12.0
Previous systemic therapy for psoriasis 39 (44.3) 47 (52.8) 43 (49.4) 47 (53.4) 176 (50.0)
  1. Values are mean ± SD or n (%). BMI, body mass index; BSA, body surface area; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.